However, with the virus showing no signs of slowing, the world needs many more tests.
And until a vaccine is deemed safe and effective, we can only hope to manage its spread with the help of COVID-19 tests in hospitals, homes, sports events, airports, schools.
Along the way, it could create a massive $10 billion market opportunity(2) with companies like XPhyto Therapeutics USA (XPHYF) Canada (XPHY.CN) racing to meet demand and quickly nearing commercialization of its CV-19 test that uses saliva and nasal-throat swabs.
That’s big news.
After all, “Filling a vial with saliva is also faster and requires less contact with other people, which is why labs around the world are investigating COVID-19 diagnostic tests that trade swabs for spit,” says Discover.(3)
But there’s a problem. Test demand is straining supply.(4)
So much so, the U.S. Congress may soon consider legislation to ensure there are enough tests to go around. In fact, according to former U.S. FDA Commissioner Scott Gottlieb, and Dr. Mark McClellan, director of the Duke-Margolis Center for Health Policy:
The company just announced that its rapid detection COVID-19 technology was validated in preliminary testing. In collaboration with German medical diagnostics firm, 3a-Diagnostics GmbH, the two confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and its universal coronavirus RNA probes in prototype lateral flow assay testing.
That’s reason No. 1 to pay close attention to XPHYF stock.
Here’s reason No. 2.
Effective drug delivery is a significant problem around the world.
In fact, according to the World Health Organization, medication adherence is as low as 50%.
“Nonadherence can account for up to 50% of treatment failures, around 125,000 deaths, and up to 25% of hospitalizations each year in the United States.”(6)
People around the world aren’t taking their medication, even though many of us spend top dollar for medications. Billions, even trillions of dollars are being spent on medications that aren’t being used. One of the top reasons for that is drug delivery.
Some folks can’t open the medication bottle. Some can’t swallow pills or capsules.
That’s where XPhyto Therapeutics can help with its revolutionary “thin film” technology that could potentially help millions of patients that don’t take their medications regularly.
In fact, Vektor, a wholly-owned subsidiary of XPhyto has developed such a product.
Using its thin film technology, Vektor created an oral dispersal film that can be dosed with exact amounts of medication, which melt in your mouth, and go straight to the bloodstream.
Plus, such “thin film” technology may be able to cut back on dosing issues.
The other major issue is potential overdosing.
Most parents give the wrong dose of liquid medication, says The New York Times.(7)
In some cases, twice as much as instructed.
In a study published in the journal, Pediatrics, it randomly assigned 2,110 parents to one of five pairings of the many possible combinations of tools and label instructions.
It’s why “many pharmaceutical companies are switching their products from tablets to fast dissolving oral thin films,” says the National Library of Medicine.(8)
Better, the company is producing oral wafers, infused with an approved therapeutic, a CBD product for the treatment of epilepsy. Helping, the U.S. Drug Enforcement Agency having just taken the CBD drug Epidiolex off the controlled substances list.
One of the top markets XPhyto can help treat is the $16.5 billion epilepsy treatment market.
At the moment, analysts at JP Morgan say Epidiolex sales could reach $1 billion by 2023.(9)
Bank of America says annual sales could hit $2.5 billion by 2027.(10)
But there’s a problem.
Epidiolex is administered orally as a liquid taken with a 5 mL or 1 mL oral syringe, which leaves it open to potential dosing errors mentioned above.(11)
Even better, based on initial dissolution testing using XPhyto’s proprietary thin film drug delivery system, the company’s oral delivery system may yield as much as a 10-to-20-times increase in bioavailability of CBD over existing oil delivery methods.
The potential solution for drug delivery is substantial.
As it nears commercialization of its CV-19 test, and revolutionizes the drug delivery market, shares of XPHYF have been explosive.
Since bottoming out at $1.74 in June 2020, the stock rallied to a recent all-time high of $2.43.
Nowadays, with a solid set of catalysts just around the corner, it wouldn’t be surprising to see this XPHYF stock begin its next leg up, especially with its new listing on the OTCQB Venture.
1) One, the company is racing to meet COVID-19 diagnostic test kit demand. Until a vaccine is deemed safe and effective, we can only hope to manage its spread with the help of COVID-19 tests in hospitals, homes, sports events, airports, schools. Along the way, it could create a massive $10 billion market opportunity.
2) Two, the company could revolutionize drug delivery with its “thin film” dissolvable tabs. In fact, with its thin film CBD technology, XPhyto Therapeutics could be a game-changer in the $16.5 billion epilepsy treatment market.
3) Three, based on initial dissolution testing using XPhyto’s proprietary thin film drug delivery system, the company’s oral delivery system may yield as much as a 10-to-20-time increase in bioavailability of CBD over existing oil delivery methods. That news alone could give GW Pharmaceuticals’ Epidiolex a run for its money.